<DOC>
	<DOCNO>NCT01637493</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability , pharmacokinetics pharmacodynamics Pegfilgrastim patient chemotherapy-induced neutropenia .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Study Pegfilgrastim Chemotherapy Patients</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Age : 18～70 year Confirmed malignant tumor patient histopathological cytological diagnosis , previously treat chemotherapy radiotherapy , suitable chemotherapy carboplatin combine taxol cyclophosphamide combine pharmorubicin Karnofsky score ≥ 70 Normal coagulation function , evidence hemorrhage , WBC ≥ 3,500 per cubic milliliter , ANC ≥ 1,500 per cubic milliliter , PLT ≥ 100,000 per cubic milliliter Normal liver , heart , kidney function Life expectancy &gt; 3 month Signed informed consent Not adequately control infection ( e.g . ANC ≥ 12,000 per cubic milliliter , temperature &gt; 38.2℃ ) Evidence metastatic disease bone marrow , malignant tumor Subjects symptomatic brain metastasis Pregnant breastfeed menstrual period female Participated 3 clinical trial nearly year ( subject ) Currently participate clinical trial , Used prescription medication could impact metabolism investigational drug , participate clinical trial within one month date screen visit Donation whole blood unit blood within three month prior start study Known hypersensitivity filgrastim product administer dose Evidence , treatment , drug alcohol abuse within one year date screening visit Other condition opinion investigator preclude enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Pegylation</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>